fbpx

Year

2017
According to William Greene, M.D., Chief Executive Officer, “Julia adds to the Board a uniquely rich background in the strategic financing, planning, partnering, and growth of both public and private biotech companies. With the recent presentation of Iconic’s Phase2a EMERGE key findings in wet Age-related Macular Degeneration, this is an opportune time to add her...
ROCKVILLE,  Md.,  and  GAITHERSBURG,  Md., April  03,  2017  (GLOBE  NEWSWIRE) Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, and Vtesse Inc. (Vtesse), a privately-held rare disease company, today  announced that Sucampo has acquired Vtesse for upfront consideration of $200 million. Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common...
The OREF Clinical Research Kappa Delta recognizes outstanding clinical research related directly to musculoskeletal disease or injury. Henrik Malchau, MD, PhD, part of the Swedish and US group, will present the study “Arthroplasty Implant Registries Over The Past Five Decades: Development, Current and Future Impact” The award will be given at the AAOS meeting, San...
“Completing enrollment in the pivotal Phase 2b/3 clinical trial of VTS-270 is a significant milestone for the NPC community and Vtesse, and we are fortunate to have exceeded our goal of 51 participants. We are extremely grateful to the study participants and their families, as well as the clinical site investigators and staff, for their...
“We are extremely pleased to extend our distribution agreement with Zimmer Biomet,” said Richard Davies, CEO of BONESUPPORT™.  “The partnership has been very successful and has resulted in the current rapid growth of our flagship product, CERAMENT in the world’s largest bone graft substitute market.  This rapid growth is building an important platform from which...
Proceeds from the financing will be used to advance Spero’s unique pipeline of antibacterials focused on drug-resistant bacterial infections. Specifically, the additional funding will enable Spero to move additional pipeline programs such as SPR994 into the clinic and advance its Potentiator program into later stage clinical trials. “We are grateful for the continued strong support...
The Lundbeck Foundation’s major research prize – The Brain Prize – goes this year to three UK-based brain researchers for explaining how learning is associated with the reward system of the brain. The prize winners have found a key to understanding the mechanisms in the brain that lead to compulsive gambling, drug addiction and alcoholism....
HARBOR follows on from a recently completed successful Phase I trial which emphasised the clinical potential of V565. The product was shown to be safe and well tolerated at high single and multiple doses, with minimal systemic exposure and no drug-induced antibodies. In addition, the trial confirmed that high concentrations of active V565 were delivered throughout the gastro-intestinal tract...
Dr Julian Gilbert, Acacia Pharma’s CEO commented: “We are delighted with these results demonstrating that BAREMSIS is safe and effective at rescuing patients who suffer PONV despite having received prior prophylaxis with standard anti-emetics. No other anti-emetic has a specific label for treating this significant unmet need and we intend to position BAREMSIS as the...
According to William Greene, M.D., Chief Executive Officer, “The EMERGE data point to ICON-1’s potential to directly address the limitations of currently approved therapies. While the study was not powered for statistical significance, we saw strong signals of biologic activity that provide a clear rationale for further clinical development. We expect to initiate further studies...
1 6 7 8 9

News

90 million to 18 Talented Researchers
19. October 2020
Søren Dinesen Lumdbeckfonden
Psychiatry research leads to prestigious science prize
13. October 2020
Christian Sandøe Musaeus Lundbeckfonden
Concentrating on Dementia
13. October 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge